Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

REGENXBIO, FUJIFILM announce manufacturing deal
March 2018
SHARING OPTIONS:

ROCKVILLE, Md.—REGENXBIO Inc. and FUJIFILM Diosynth Biotechnologies have inked an agreement covering the manufacture of REGENXBIO's lead product candidates, including RGX-314 and RGX-501, to support late-stage clinical development and early commercialization. Per the agreement, REGENXBIO will have guaranteed capacity for the supply of NAV AAV drug substance manufactured under GMP at large scale for three years, with the potential to extend the agreement for another three years.
 
“We look forward to strengthening our relationship with REGENXBIO, a leader in the development of innovative gene therapy products providing hope for patients,” said Martin Meeson, president and chief operating officer of FUJIFILM Diosynth Biotechnologies. “With our strong track record of execution, and with facilities and systems that are suitable for late-stage and commercial production, we are well positioned to support the manufacturing needs of REGENXBIO as it continues to move multiple product candidates toward commercialization.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.